Although the overall incidence of osteosarcoma is low the occurrence of osteosarcoma in a setting of multiple primary tumours is not infrequent. Association between osteosarcoma and other malignancies is frequently the result of treatment, but can also be the result of genetic predisposition. The aim of our study is to establish the incidence of osteosarcoma associated with other malignancy in the Dutch population and to find out if rare osteosarcoma subtypes occur in higher frequency in patients with secondary malignancies and who are suspected to have a genetic predisposition to malignancy. Methods: Of all patients with the diagnosis of osteosarcoma registered between 1975 and May 2000 in the Dutch National Pathology Register, all patients were selected who had an other malignancy before or after their diagnosis of osteosarcoma. In a second step only those patients were retained for further study that had a history of retinoblastoma or a history of malignancy before the age of 45. Of these patients the histological material was reviewed and osteosarcomas were subtyped as common, chondroblastic, fibroblastic, anaplastic, telangiectatic, osteoclast rich or small cell. As a control 570 patients entered in the database of the European Osteosarcoma Intergroup were used. Results: In total 1145 patients had a diagnosis of osteosarcoma, 65 had a history of multiple primary tumours. 7 of these patients were rejected for further analysis, 2 were retinoblastoma patients and 22 had their malignancies before the age of 45. 47% of these patients had an osteosarcoma subtype other than common as opposed to 29% in the control group. If only those patients were selected in which there was no relation with treatment and second malignancy, 90% had subtypes other than common. Conclusion: a non-common subtype of osteosarcoma may be predictive for a patient to be a member of a cancer syndrome family. Objective of the study: The study of gene expression profiling (with cDNA microarrays) and protein expression (by co-immuno precipitation) help in the identification of candidate genes and proteins involved in oncogenic pathways in the search of novel therapeutic targets. Methods: In a phenotypic Li-Fraumeni family, a germline p53 mutations at codon 220 (amino acid change from tyrosine to serine) was identified. We generated by site directed mutagenesis a plasmid encoding the p53SER220 mutation (pLp53-S220) and transfected fibroblasts from p53 -/-mice (F10) with this vector. Introduction: Recently we documented a strong association between the occurrence of cartilaginous tumours (enchondroma, chondrosarcoma) and breast cancer in the same patient, using a nation-wide case-control study. This study revealed an odds ratio of 7.62 for a potential association of breast and cartilaginous tumours, pointing statistically strongly towards a genetic trait. This is furthermore corroborated by the age of onset in patients with breast cancer as the first tumour, which is about 10 years earlier than breast cancer in the general population. Objective: We have investigated clinical and phenotypic properties of the breast-and the cartilaginous tumours in patients with both tumour types to identify a possible characteristic spectrum for this hereditary trait. Methods: Using the national pathology database the tissue blocks of all patients reported to fulfil the associated tumours mentioned were retrieved. Reported diagnoses were reviewed; breast cancer specimens were classified and histologically. In addition the cartilaginous tumours were analysed with emphasis on the central versus peripheral localisation in the skeleton as previous studies proved a different molecular mechanism to be operative in the different subtypes. Expression of p53, Bcl2, Her2-neu, p16, p21 oestrogen and progesterone receptor and E-cadherin was determined by immunohistochemistry.
Although the overall incidence of osteosarcoma is low the occurrence of osteosarcoma in a setting of multiple primary tumours is not infrequent. Association between osteosarcoma and other malignancies is frequently the result of treatment, but can also be the result of genetic predisposition. The aim of our study is to establish the incidence of osteosarcoma associated with other malignancy in the Dutch population and to find out if rare osteosarcoma subtypes occur in higher frequency in patients with secondary malignancies and who are suspected to have a genetic predisposition to malignancy. Methods: Of all patients with the diagnosis of osteosarcoma registered between 1975 and May 2000 in the Dutch National Pathology Register, all patients were selected who had an other malignancy before or after their diagnosis of osteosarcoma. In a second step only those patients were retained for further study that had a history of retinoblastoma or a history of malignancy before the age of 45. Of these patients the histological material was reviewed and osteosarcomas were subtyped as common, chondroblastic, fibroblastic, anaplastic, telangiectatic, osteoclast rich or small cell. As a control 570 patients entered in the database of the European Osteosarcoma Intergroup were used. Results: In total 1145 patients had a diagnosis of osteosarcoma, 65 had a history of multiple primary tumours. 7 of these patients were rejected for further analysis, 2 were retinoblastoma patients and 22 had their malignancies before the age of 45. 47% of these patients had an osteosarcoma subtype other than common as opposed to 29% in the control group. If only those patients were selected in which there was no relation with treatment and second malignancy, 90% had subtypes other than common. Conclusion: a non-common subtype of osteosarcoma may be predictive for a patient to be a member of a cancer syndrome family. Objective of the study: The study of gene expression profiling (with cDNA microarrays) and protein expression (by co-immuno precipitation) help in the identification of candidate genes and proteins involved in oncogenic pathways in the search of novel therapeutic targets. Methods: In a phenotypic Li-Fraumeni family, a germline p53 mutations at codon 220 (amino acid change from tyrosine to serine) was identified. We generated by site directed mutagenesis a plasmid encoding the p53SER220 mutation (pLp53-S220) and transfected fibroblasts from p53 -/-mice (F10) with this vector.
B23 Gene and Protein Expression Profiling in Fibroblasts Carrying a Li-Fraumeni p53 Germline Mutation that
Drug sensitivity (assessed by IC50 value) of the fibroblasts carrying the mutation was evaluated for doxorubicin, cisplatin and 5-florouracil. Fibroblasts carrying the p53SER220 mutation showed a selective resistance for doxorubicin. We treated with doxorubicin the p53SER22, p53 wild type and p53 -/-fibroblasts and we evaluated the gene expression profiles of these cells at different time points. Moreover, we performed a co-immuno precipitation with a p53 antibody in cellular lysate of p53 wild type and p53SER220 fibroblasts also treated with doxorubicin to evaluate the protein expression profiles at different time points.
Results: Distinct patterns of gene expression for the three different fibroblasts were identified. Additionally, lists of doxo-dependent and doxo-independent activated genes were determined. Analysis of these gene lists pinpoint a number of signal transduction and cell cycle genes differentially expressed. Co-immuno precipitation experiments resulted in the presence of additional bands 24 h after doxorubicin treatment when the p53SER220 fibroblasts were compared with the wild-type cells and these bands could identify proteins involved in the chemoresistance.
Conclusion:
Several genes and protein are expressed according to the different p53 status after doxorubicin treatment. These studies may evolve in development of novel therapeutic strategies. (Table I) . Mutations were nucleotide changes except two cases with frameshift mutations. Introduction: Recently we documented a strong association between the occurrence of cartilaginous tumours (enchondroma, chondrosarcoma) and breast cancer in the same patient, using a nation-wide case-control study. This study revealed an odds ratio of 7.62 for a potential association of breast and cartilaginous tumours, pointing statistically strongly towards a genetic trait. This is furthermore corroborated by the age of onset in patients with breast cancer as the first tumour, which is about 10 years earlier than breast cancer in the general population. Objective: We have investigated clinical and phenotypic properties of the breast-and the cartilaginous tumours in patients with both tumour types to identify a possible characteristic spectrum for this hereditary trait. Methods: Using the national pathology database the tissue blocks of all patients reported to fulfil the associated tumours mentioned were retrieved. Reported diagnoses were reviewed; breast cancer specimens were classified and histologically. In addition the cartilaginous tumours were analysed with emphasis on the central versus peripheral localisation in the skeleton as previous studies proved a different molecular mechanism to be operative in the different subtypes. Expression of p53, Bcl2, Her2-neu, p16, p21 oestrogen and progesterone receptor and E-cadherin was determined by immunohistochemistry.
B24 Somatic and Germinal Alteration of the TP53 Gene in Pediatric Osteosarcoma

Results and Conclusion:
No case of chondrosarcoma nor enchondroma was reported in the Dutch BRCA1 and BRCA2 database, pointing to a trait which is different from the aforementioned breast cancer syndromes. Remarkably all cartilaginous tumours are of one common histological subtype being centrally localised whereas no peripheral cartilaginous tumour was registered. Furthermore the cartilaginous tumours showed a significantly higher p16 and p21 staining. The breast tumours were histologically heterogeneous with varying differentiation grade. Characteristics of the breast cancers: 10 years earlier age of onset, higher mitotic count, less lymph infiltrate, high ER staining and high p53 staining. Results: All the cell lines tested expressed high levels of the MET proto-oncogene and two of them (MG-63 and IOR/OS10) coexpressed HGF. Four cell lines (U-2OS, Saos-2, IOR/OS9 and IOR/OS10) showed the activation of the MAPK cascade suggesting a common proliferative role of the HGF. Two lines (U-2OS, Saos-2) showed activation of PKB/Akt, which is known to be involved in migration mediated by HGF receptor. These data are confirmed by proliferation and motility assay in vitro. Conclusion: These data suggest that HGF activates both the mitogen and motogen machinery in osteosarcoma cells, promoting the malignant behaviour of these cells at different steps. Inhibition of the paracrine/autocrine HGF/Met circuit may represent a promising target for innovative therapies in osteosarcoma. 
B32 Telomerase Activity and Telomere Length in
B33 Protease Inhibitors as Prognostic Factors in High Risk Soft Tissue Sarcomas (STS)
Matrix metalloproteinases (MMPs) degrade components of the extracellular matrix and are implicated in tissue remodelling and tumour infiltration. Tissue inhibitors of metalloproteinases (TIMPs) inhibit enzymes of the MMP family and preserve stromal integrity, thus inhibiting tumour migration. An unbalance in this proteolytic activity may contribute to tumour invasiveness and metastasis. The present study evaluated MMP2 and -9 tissue enzymatic activity as well as the expression and serum level of their inhibitors TIMP1 and -2, in selected patients with high risk STS, to evaluate the alterations of proteolytic cascade in malignancy progression.
Methods:
The level and distribution of MMP2, MMP9, TIMP1 and TIMP2 expression were evaluated in 69 biopsies of primary STS including: 15 high grade liposarcomas, 19 synovial sarcomas, 7 high grade MPNST and 28 high grade MFH. The study was carried out by immunohistochemistry and zymography. To test plasma TIMP1 and -2 concentration, blood samples were collected from 53 patients before treatment and measured with enzyme-linked immunoabsorbent assay (ELISA). Histological types included 20 liposarcomas, 13 synovial sarcomas and 20 MFH. 58 healthy subjects were included as control group.
Results: By zymography analysis, 52% and 49% of the 69 tumours had significant enzymatic activity of MMP2 and MMP9 respectively. TIMP2 expression was inversely correlated to poor prognosis in terms of disease free survival and overall survival (p<0,003, p<0,006 respectively). In the metastatic group, 78% patients lacked TIMP2 expression versus 43% in the disease free patients. Plasma concentration of TIMP1 and -2 in 53 STS patients revealed significantly lower levels compared to controls.
Conclusion:
The Results of this study showed that TIMP1 and -2 are involved in the progression of high grade STS.
B34 Primary Malignant Tumours of Bone Following Previous Malignancy J.T. Patton, S. Sommerville, R. Grimer Royal Orthopaedic Hospital, Birmingham, United Kingdom
The purpose of this study is to emphasise the necessity for caution in assuming the diagnosis of a metastasis when a solitary bone lesion is identified following a prior malignancy. Bone lesions occurring in patients who have previously had a malignancy are generally assumed to be a metastasis from that malignancy. We reviewed 60 patients with a previous history of malignancy, who presented with a bone lesion that was subsequently found to be a different primary sarcoma of bone. These second malignancies occurred in three distinct groups of patients. 1. Patients with original tumours well known to be associated with second malignancies (5%) 2. In patients whose second malignancies were likely to be due to the previous treatment of their primary malignancy (40%) 3. In patients in whom there was no clearly defined association between malignancies (55%) Inappropriate biopsy and treatment of primary bone sarcomas compromises limb salvage surgery and can affect patient mortality. We would advise referral of any aggressive solitary bone lesion to a regional bone tumour service for further assessment and biopsy rather than to assume the lesion is a metastasis.
B35 Protease Inhibitors as Prognostic Factors in High Risk Soft Tissue Sarcomas (STS)
Matrix metalloproteinases (MMPs) degrade components of the extracellular matrix and are implicated in tissue remodelling and tumour infiltration. Tissue inhibitors of metalloproteinases (TIMPs) inhibit enzymes of the MMP family and preserve stromal integrity, thus inhibiting tumour migration. An unbalance in this proteolytic activity may contribute to tumour invasiveness and metastasis. The present study evaluated MMP2 and -9 tissue enzymatic activity as well as the expression and serum level of their inhibitors TIMP1 and -2, in selected patients with high risk STS, to evaluate the alterations of proteolytic cascade in malignancy progression. The level and distribution of MMP2, MMP9, TIMP1 and TIMP2 expression were evaluated in 69 biopsies of primary STS including: 15 high grade liposarcomas, 19 synovial sarcomas, 7 high grade MPNST and 28 high grade MFH. The study was carried out by immunohistochemistry and zymography. To test plasma TIMP1 and -2 concentration, blood samples were collected from 53 patients before treatment and measured with enzyme-linked immunoabsorbent assay (ELISA). Histological types included 20 liposarcomas, 13 synovial sarcomas and 20 MFH. 58 healthy subjects were included as control group. By zymography analysis, 52% and 49% of the 69 tumours had significant enzymatic activity of MMP2 and MMP9 respectively. TIMP2 expression was inversely correlated to poor prognosis in terms of disease free survival and overall survival (p<0,003, p<0,006 respectively). In the metastatic group, 78% patients lacked TIMP2 expression versus 43% in the disease free patients. Plasma concentration of TIMP1 and -2 in 53 STS patients revealed significantly lower levels compared to controls.
Conclusion:
The Results of this study showed that TIMP1 and -2 are involved in the progression of high grade STS. 
B36 Using Spectral
Israel
Rhabdomyosarcoma (RMS) is histologically divided into two main subtypes: embryonal (ERMS) and alveolar (ARMS), each associated with different genetic changes. ARMS is characterized by the fusion of FKHR at 13q14 with either PAX3 at 2q35, or, less commonly, with PAX7 at 1p36, while no consistent chromosomal abnormalities are observed in ERMS. To identify novel genetic changes associated with RMS, cytogenetic and arraybased comparative genomic hybridisation (array-based CGH) analyses were employed on eight pathologically-diagnosed RMS tumours. Of the 3 ERMS specimens examined, 2 demonstrated a normal karyotype, while the third sample displayed changes in several chromosome including 2, 7 and 8. In ARMS, structural rearrangements were detected in 4 of the 5 tumours tested. Involvement of 13q14 region was detected in 3 cases, but only one case showed a characteristic t(2;13), in addition to other aberrations. The other 2 cases displayed ins(13;13) (q14;q1?) in a complex karyotype, and a t(13;20) (q14;q13.3), in addition to a large number of double minutes (dmins), respectively. Spectral karyotyping analysis identified the dmins origin as chromosome 13, while the dmins detected in the last tumour as a sole cytogenetic aberration, were classified as derived from chromosome 1. Array-based CGH analysis of 57 genes commonly amplified in cancer, detected a single co-amplification of GLI (2.5-fold) and SAS/CDK4 (3.2-fold) in the ARMS specimen harbouring the t(13;20) and dmins(13). Conclusion: This data demonstrates that using a combination of advanced molecular and cytogenetic techniques, namely SKY and array-based CGH, allowed us to better characterize some of the genetic changes which may contribute to RMS tumourigenesis, in particular, the dmins and gene amplification events. Soft tissue tumours constitute a heterogeneous and complex group of mesenchymal lesions. Chromosomal analysis and molecular cytogenetic approaches had a great impact on the classification and diagnosis of these tumours. However, because of the lack of molecular markers, it is still difficult to discern in a number of tumour types benign lesions from malignant ones based purely on histology. We set up a complex molecular approach to analyse new cases by using a multicolour FISH (COBRA FISH) approach and comparative genomic hybridisation (CGH) for genome-wide screening and determination of alteration of the tumour genome. Multifluorescent in situ hybridisation using whole chromosome painting probe sets may help to pinpoint recurrent aberration, which would improve the (sub)classification of different entities. Complex chromosomal rearrangements are further characterised by hybridisation-based staining of pan-centomeric/telomeric and subtelomeric sequences. Candidate regions are analysed by highresolution BAC/PAC hybridisations on small or large-scale arrays to determine new genes involved in the disease. The detected rearrangements are confirmed on archived materials by using FISH or PCR based approaches. So far we have analysed more than 40 new cases of various tumour types and the approach is illustrated with representative cases. through factors that are common in normal bone formation in the dog, and has a negative effect on survival data. Telomeres are structures at the end of eukaryotic chromosomes that are shortened with each cellular division, being one of the limiting factors for cellular proliferation. Most of the chemotherapy treatments are designed to act against immortal cells, which have shorter telomeres due to their higher proliferative rates. Objective: To compare the TRF (Telomeric Restriction Fragments) length of blood samples from paediatric osteosarcoma (OS) and Ewing's sarcoma (ES) patients before and after the chemotherapy treatments. Methods: Blood samples were obtained from 15 OS and 18 SE patients at the beginning as well as after the chemotherapy cycles. The TRF length was measured by Southern Blot. Results: TRF length at the beginning of treatment was statistically shorter in patients with survival periods >2 years, compared to those patients who died within 2 years after diagnosis (p=0.032). This difference was conserved when the survival period considered was increased to 5 years (p=0.005). The TRF length of samples at the beginning and at the end of treatment was statistically different in patients with more than either 5 or 2 years of survival, opposite to those patients who died within 2 years after completion of chemotherapy, whose telomeres had the same length at the beginning and after treatment (Table I) . Table I : Difference between the TRF length at the beginning and after treatment in relationship to survival. Survival Number of samples, Difference in TRF length < 2 years 90.9 Kbp=0.041 2-5 years 130.5 Kbp=0.046 > 5 years 110.1 Kbp=0.563 Conclusion: Bone tumour patients that have shorter TRFs lengths at the beginning of chemotherapy have longer survival rates than those patients with longer TRFs. The difference between the TRF length at the beginning and at the end of treatment seems to be related to survival in bone cancer paediatric patients undergoing chemotherapy. 
B40 Multiple Primary Malignancies in Patients with
